Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:51:09.009Z.
Calculation as of: 2026-10-06T15:51:09.009Z.
Quote observation: 2026-10-06T15:50:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e78bbdb3a8988fdd9fdd63a4dcf124b38851ed281a9b1f93071349952e7e00d5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$44.11M
Price/OCF Ratio
N/A
TTM Avg
9.67
3Y Avg
15.53
5Y Avg
36.04
Market Cap
$45.22M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$48.05M
Price/OCF Ratio
N/A
TTM Avg
73.59
3Y Avg
628.92
5Y Avg
487.62
Market Cap
$40.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CVRx, Inc. (CVRX) | $44.36M | N/A | N/A | N/A | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $44.20M | N/A | N/A | N/A | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $44.11M | N/A | 9.67 | 15.53 | 36.04 |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.22M | N/A | N/A | N/A | N/A |
| DarioHealth Corp. (DRIO)vs › | $44.35M | N/A | N/A | N/A | N/A |
| Precipio, Inc. (PRPO)vs › | $41.92M | 38.11 | 48.39 | 39.24 | 39.24 |
| Filana Therapeutics, Inc. (FLNA)vs › | $41.65M | N/A | N/A | N/A | N/A |
| Precision Optics Corporation, Inc. (POCI)vs › | $48.05M | N/A | 73.59 | 628.92 | 487.62 |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $40.06M | N/A | 33.35 | 46.22 | 46.22 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
